key: cord-0964239-ve4svltk authors: Farhan, Hasan Ali; Yaseen, Israa Fadhil title: Perceptions of the Cardiologists and Oncologists: Initial Step for Establishing Cardio-Oncology Service date: 2021-11-24 journal: Front Cardiovasc Med DOI: 10.3389/fcvm.2021.704029 sha: 89ab4116632f3a584146bc7897ced50b3be29dd4 doc_id: 964239 cord_uid: ve4svltk Background: Over the last years, there was no established cardio-oncology service in Iraq and no firm data about the incidence of cardiovascular disease (CVD) among patients with cancer. As an initial step, we decided to conduct a national cardio-oncology online survey for cardiologists, oncologists, and their residents which would help us to understand the expected prevalence, problems, and readiness for collaboration between the two specialties. Objectives: For evaluating the current national practice in the cardiology and oncology specialty fields and to identify the hidden gaps associated with the development or worsening of CVD among patients with cancer. Methods: An online survey including 19-question for cardiologists/cardiology residents (CCRs) and 30-question for oncologists/oncology residents (OORs) about cardio-oncology service was sent to them including all Iraqi cities using Google document form during December 2020. Results: The total number of responses was 164, mainly 62.2% from CCRs while 37.8% from OORs. Hypertension was the main baseline risk factor (71%). A 77.5% of CCRs prescribe cardiovascular drugs vs. 35.5% by OORs. About 76.5% of CCRs and 79% of OORs are facing difficulties in the management of patients with cancer with established CVD. CVD was the leading cause of both hospitalization (30.7%) and mortality (48.4%). About 62.8% of CCRs and 64.5% of OORs have an interest to work in cardio-oncology service. Conclusion: Based on the perception of cardiologists and oncologists, CVD is the main cause of hospitalization and mortality among patients with cancer. High interest among CCRs and OORs to work in cardio-oncology service. Positive initiatives are available to take the action plan in this emerging field. Cardio-oncology is an emerging specialty and service with a team-based approach that includes cardiologists, oncologists, and hematologists working collaboratively for optimizing cardiovascular risk stratification, prevention, and treatment for all patients with cancer and survivors to guide best practice by bridging the gaps in knowledge and needs including supporting patients with cancer to improve continuing of their cancer therapies without interruption by the cardiovascular disease (CVD) (1) (2) (3) (4) . First cardio-oncology service emerged in 2010 (1, 4) , therefore, such essential service was not available worldwide including Iraq. A descriptive study in the United Kingdom including data over 5-year activity from cardio-oncology service reported that baseline CVD and myocardial toxicity are higher than that was documented in previous studies (5) . This is why continuing national and international research in the cardiooncology field is of high importance for a better understanding of the current practice and optimization of cardio-oncology services. In 2019, the Iraqi Cardio-Oncology Program was founded by a senior consultant cardiologist and his mentee the cardiology clinical pharmacist to support the initiation of cardio-oncology services and as an initial step for evaluating the current national practice and uncovering the hidden gaps associated with the development or worsening of CVD especially during a very critical time of COVID-19 era, therefore, it was decided to conduct an online survey. An online survey has several advantages, including low costs, real-time access, not time-consuming, and respondents may be more willing to participate and had documented the need to improve the care of patients (2, 6) . The study was approved by the Department of Continuing Medical Education at the Iraqi Board for Medical Specializations. An online survey link including 19 questions for cardiologists/cardiology residents (CCRs) and 30 questions for oncologists/oncology residents (OORs) about cardiooncology service was sent to participants who are working in cardiology and oncology sites in all 18 Iraqi cities using Google document form in December 2020. The link was shared with the participants by sending a message on WhatsApp or Viber applications for responding to the survey voluntarily. The message was sent either individually or by sharing it on WhatsApp or Viber groups for cardiologists, oncologists, and their residents. Questions were divided into three categories: (1) about demographics of participants, (2) questions about current practice, and (3) questions about their opinions about cardiooncology service. Some of the questions in categories two The statistical analysis was performed using Excel for Mac, Version 15.13.3. Most of the responders were male and specialists; cardiologists and oncologists, with age younger than 66 years old. Results are available in Table 1 . Hypertension (HTN) is the most common baseline CVD among patients with cancer according to the OOR experiences (71%), while heart failure (HF) was the most common one as a result of the CCR responses (60.3%). The results of these questions are available in ( Table 2 and Figures 1-7) . The majority of CCRs (86.3%) and OORs (85.5%) believe that the establishment of cardio-oncology services will improve the outcomes of patients. The details are available in (Table 3 and Figure 8 ). This survey showed that HTN was the most common preexisting CVD among patients with cancer according to the response of about two-third of OORs, while none of the CCRs mentioned it responses of OORs showed that hypertension is the most common cardiac disease accounting for 71%, followed by HF 12.9%, pericardial effusion 6.5%, ischemic heart disease 6.5%, and arrhythmia 3.2%. While CCRs' responses were HF 60.8%, pericardial effusion 36.3%, arrhythmias 2%, and ischemic heart disease 1% ( Figure 1 ). Responses from all cardiology participants and 48 (77.4%) oncology participants showed that ACEI/ARB are the most frequent cardiovascular drugs to be prescribed, followed by beta-blocker by CCRs and anticoagulant by OORs ( Figure 2 ). 6. Do you face any difficulty in taking management action plan among patients with cancer with CVD? The difficulty was faced among (76.5%) of CCRs when a patient with cancer refers to them to decide to continue or withhold chemotherapy/radiotherapy due to cardiac disease, and (79%) of OORs are facing difficulty in planning management strategy of cancer in a patient with cardiac disease. 7. What's the most common cancer type presents to you suffering from cardiac disease due to chemotherapy and radiotherapy?* Breast cancer is the most common cancer type associated with CVD induced by both chemotherapy (66.7%) and radiation therapy (52.9%). Results are available in Figure 3 . 8. What's the most common cardiac disease due to chemotherapy and radiotherapy is developed among your patients?** HF is the most common CVD induced by chemotherapy (64.5%) and radiation therapy (45.2%).Results are available in Figure 4 . 9. Do you face any interaction between cardiovascular drugs and anticancer?** About 40.3% of OORs' responses reveal that they are facing interaction between cardiovascular drugs and anticancer therapy. 10 . What's the most complications of chemotherapy do you face in patients with cancer?** Renal impairment is the most common complication of chemotherapy (32%) while CVD is the sixth one (5%). Results are available in Figure 5 . therapy the incidence of de novo or worsening HTN ranging between 17 and 80% (6-9). It is known that CVD and cancer are sharing the same risk factors and preventive strategies, and pre-existing CVD in newly diagnosed patients with cancer may attribute to increasing morbidity and mortality, however, limited studies focus light on the prevalence of pretreatment cardiovascular risk factors (10, 11) . A recently published JACC perspective can be considered as a roadmap to improve education FIGURE 7 | Central illustration showing the current practice and the required action plan to protect heart health among patients with cancer. Hypertension is the most common baseline cardiovascular risk factor among cancer patients according to the current practice which can be the leading cause of cardiovascular hospitalization and mortality. The action plan is required to protect the heart health of cardio-oncology patients by baseline cardiovascular risk assessment and teamwork. and training in the field of cardio-oncology to prevent CVD among patients with cancer rather than direct treatment (12) . Regarding the most common CVD induced by chemotherapy and radiation therapy, both the CCRs and OORs reported HF as the first complication, then CCRs reported HTN as the second cardiac complication followed by myocardial infarction, while OORs reported the second complication is myocardial infarction followed by HTN, therefore, both the CCRs and OORs confirm that HTN incidence is among the first top three complications of cancer therapy. HF is a known complication of cancer and radiation therapies particularly in breast cancer, in addition, chest radiation accelerates atherosclerosis and cardiomyopathies (2, (13) (14) (15) . Systemic HTN can be associated with both chemotherapies and immunologic therapies thus further increasing the burden of cardiovascular toxicities, it was estimated that novel cancer therapy can induce HTN by 24% (7) (8) (9) (10) (11) (12) (13) . Moreover, resistant HTN and hypertensive crisis are associated with surgery or radiotherapy involving the head or neck (8) . Therefore, treatment of HTN is one of the cornerstones for reducing the major cardiovascular events such as HF and end-stage renal failure in addition to overall mortality (7) . The most common cardiovascular drug prescribed was ACEI/ARB as reported by both CCRs and OORs followed by anticoagulant and aspirin prescribed by OORs and beta-blockers prescribed by CCRs, this may be interpreted by the OORs use of ACEI/ARB for treating HTN among patients with cancer as a first-line drug as mentioned above. While ACEI/ARN and BB explain that CCRs prescribe them for patients with cancer who are (at risk) of CVD and patients with HF. In UK-based cardio-oncology service, it was also documented that beta-blockers and ACEI/ARB were the most prescribed drug for the referred cardio-oncology patients (6) . Beta-blockers are considered cardioprotective drugs among patients with cancer for their beneficial effect in CVD and for the growing evidence regarding their role in breast cancer as it is associated with a significantly lower rate of metastasis particularly with propranolol, significantly reducing HF incidence during anthracyclines therapy with or without trastuzumab, and reducing of cancer-specific mortality rate among patients with prostate cancer whether using cardioselective or noncardioselective beta-blockers (16) . Most of the CCRs and OORs reported that the main cancer type associated with CVD related to chemotherapy and radiation therapy are breast cancer and lung cancer, therefore, focusing attention on these two types of cancer particularly baseline risk factors assessment is important to prevent CVD complications. Current evidence also reported breast cancer as the first type of malignancies associated with CVD and the cause of referral (6, 14) . More than two-third of OORs reported facing drug-drug interactions, despite this, they are checking for drug-drug interaction only when it is required depending on symptoms as reported by more than two-third of OORs and by about half of CCRs, i.e., checking after the interactions were taking place and this will increase the incidence of drugdrug interactions. Documented harmful drug-drug interactions among patients with cancer who are receiving oral cancer therapy are very common reaching 46% including 15% major and 83% moderate harmful interactions, 14% of interactions including 1. For cardio-oncology teamwork for the management of cancer patient, which specialties do you think it is important to be available? (please choose all options you think it is mandatory) The main selected specialties are shown in (Figure 8) , with cardiologist being the highest recommended expert to be in the team as responding by CCRs (87.3%) and OORs (72.6%). Other specialties suggested, namely: surgeon, hematologist, radiologist, nuclear medicine specialist, nephrologist, psychologist, pulmonologist, nutritionist, and echocardiographer. 2. Do you think it is important to establish a cardio-oncology service for better outcomes of patients with cancer? Most of CCRs (86.3%) and OORs (85.5%) believe it is important to establish cardio-oncology service, (12.8%) and (14.5%) of CCRs and OORs; respectively, think it is maybe important to establish such service, while only (1%) of CCRs do not think it is important. 3. If there is a plan to establish cardio-oncology service, where is the best place for it? Most of CCRs (76.5%) and OORs (66.1%) suggest that the best place for cardio-oncology service to be at the academic center rather than a community center, and regarding the best site for this service, (75.8%) of OORs suggested being at oncology site while (52%) of CCRs preferred to be at a cardiology site. cancer therapy and QT interactions (17). According to the OORs response of survey, CVD is the sixth complication of chemotherapy, however, the majority of the response of OORs regarding the main cause of hospitalization and mortality among cardio-oncology patients is CVD, this may be explained by uncontrolled baseline CV risk factors and underestimating of evaluation drug-drug interactions which may increase CVD or risks which exacerbate CVD leading to hospitalization and mortality. Evidence showed that cardiovascular hospitalization is the main cause of prostate cancer and the third cause of noncancer hospitalization among patients with cancer in general and noncancer mortality is highest among patients with colorectal, bladder, kidney, endometrium, breast, prostate, and testis cancers with heart disease being the most common cause (18, 19) . Other findings in this study reported more than twothird of CCRs and OORs are facing difficulties while taking management action plans among cardio-oncology patients which necessitates teamwork and availability of guidelines and protocols for the management of cardio-oncology patients. Most CCRs and OORs agreed that the cardio-oncology team should include cardiologists, however, most CCRs believe that the team should include also oncologists, internal medicine specialists, and pharmacists, in addition to other specialties, however, the minority of OORs tend to include other specialties among the cardio-oncology team. It is known that cardiologists have an important role in the prevention of cardiovascular complications among patients with cancer through a comprehensive evaluation of cardiovascular risk factors and physical examination before initiation of cancer therapy (20) , however, other specialties are also essential to be included among the cardio-oncology team for better outcomes, for example, the availability of pharmacists to prevent or minimize harmful drug-drug interactions which commonly occur (17). The proposed typical cardio-oncology team includes cardiologists, oncologists, hematologists, general practitioners, pharmacists, nurses, cardiac surgeons, radiologists, clinical laboratory specialists, palliative care team, psychologists, social workers, and data managers, depending on hospital size and organization (20) . The current survey discovered several encouraging and strength points for the initiation of cardio-oncology services in Iraq including more than one-half of both CCRs and OORs have the interest to work in cardiooncology service, most of the CCRs and OORs believe in the importance of holding a monthly cardio-oncology meeting to discuss together challenging cardio-oncology cases, and twothird of CCRs want to include cardio-oncology training in cardiology curriculum and almost all OORs wish to include such training in the oncology curriculum, all these points are promising for the near future improvement in the standard of cardiac services for patients with cancer to achieve the mission of our cardio-oncology program by protecting heart health among cardio-oncology patients. This study depended on an online survey reflecting the expert opinions, therefore, the real prevalence of baseline cardiovascular risk factors and other results among patients with cancer need to be documented by clinical researchers and registries. In conclusion, according to the survey-based data depending on the perception of cardiologists and oncologists, CVD is the leading cause of hospitalization and mortality among cardio-oncology patients, despite that CVD may be considered as the sixth rank complications among cancer therapy. There are essential needs to focus on the baseline CV risk stratification among patients with cancer to prevent CVD or CVD worsening by emphasizing on teamwork. There is an increasing interest among cardiologists, oncologists, and their residents in cardio-oncology teamwork and cardio-oncology training. It is time to take the action plan to change the current real practice to bridge the gap in the cardio-oncology service and to support clinical researches and registries in this field. The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. HF and IY contributed equally in study design, writing, review, and approve for publication. IY performed the statistical analysis. Cardio-oncology: what you need to know now for clinical practice and echocardiography Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the cardio-oncology study group of the heart failure association of the European society of cardiology in collaboration with the international cardio-oncology society Activity and outcomes of a cardio-oncology service in the United Kingdoma five-year experience Research methods in healthcare epidemiology: survey and qualitative research Hypertensive cardiotoxicity in cancer treatment-systematic analysis of adjunct, conventional chemotherapy, and novel therapiesepidemiology, incidence, and pathophysiology Hypertension in cancer patients The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgen deprivation therapy in British Columbia Cardiovascular and cancer risk: the role of cardio-oncology Shared risk factors in cardiovascular disease and cancer Cardio-oncology education and training: JACC council perspectives Preventive cardio-oncology: the time has come Treatment-related complications of systemic therapy and radiotherapy Common cardiovascular complications of cancer therapy: epidemiology, risk prediction, and prevention Beta-Blockers and Cancer: Where Are We? Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs Unplanned hospitalization among individuals with cancer in the year after diagnosis Causes of death among cancer patients Cardio-oncology services: rationale, organization, and implementation Special thanks to all participants in Iraq who responded to this survey. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.Copyright © 2021 Farhan and Yaseen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.